Company Announcement

Nykode Therapeutics to Showcase APC-Targeted DNA Vaccine Platform at 3rd Annual Personalized Cancer Vaccine Summit

Oslo, Norway, November 19, 2026 — Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of cancer vaccines, today announced that Chief Executive Officer, Michael Engsig, and Chief Scientific Officer and Co-founder, Agnete Fredriksen, will participate in the 3rd Annual Personalized Cancer Vaccine Summit, taking place December 1–3, 2026 in Boston, MA.

Nykode's leadership will contribute to three sessions during the summit, sharing the company's perspectives on the development, manufacturing, and clinical translation of personalized cancer vaccines.

“As interest in the field of individualized neoantigen cancer vaccines continues to grow, attention is increasingly turning to how these treatments can be delivered to patients at scale,” said Agnete Fredriksen, Chief Scientific Officer and Co-founder of Nykode Therapeutics. “We believe our APC-targeted DNA platform offers a differentiated approach, supported by encouraging clinical immunogenicity data and an established manufacturing process. We look forward to contributing to discussions on the opportunities and challenges shaping the future of personalized cancer vaccines.”

Nykode's work in personalized cancer vaccines is being advanced through VB10.NEO, its wholly owned, DNA-based individualized neoantigen therapy (INT). Built on Nykode's proprietary antigen-presenting cell (APC)-targeting technology and NeoSELECT™, its AI-driven neoantigen selection engine, VB10.NEO is designed to deliver selected antigens to APCs to generate broad, potent, and long-lasting antigen-specific immune responses.

The company has established an end-to-end manufacturing process for VB10.NEO, achieving 100% manufacturing success across two clinical trials. Further optimization of the manufacturing process reduces the current turnaround-time from biopsy to product release to less than six weeks with a clear path to further reductions by additional consolidation under “one roof”. Its plasmid DNA-based platform also offers potential advantages in manufacturing complexity, and cost of goods compared with alternative approaches.

Clinical data across two trials in patients with advanced solid tumors have demonstrated vaccine-specific immune responses in 88–100% of patients, including de novo T-cell responses in 85% of patients. These responses remained durable for more than one year after the final dose, supporting the potential of Nykode's platform to generate strong and sustained immune responses.

Summit Program and Presentation Details

1. **Workshop:** Streamlining Manufacturing, Analytics & Supply Chain Operations to Accelerate Delivery of Personalized Cancer Vaccines
   Speaker: Michael Engsig
   Date: Tuesday, December 1, 2026
   Time: 9:00 a.m.

2. **Seminar:** From Promise to Practice: Enabling the Next Generation of Personalized Cancer Vaccines
   Speaker: Agnete Fredriksen
   Date: Thursday, December 3, 2026
   Time: 9:00 a.m.

3. **Panel Discussion:** Comparing Personalized vs. Off-the-Shelf Cancer Vaccines to Choose the Right Strategy for the Right Indication
   Panelist: Agnete Fredriksen
   Date: Thursday, December 3, 2026
   Time: 11:30 a.m.

About Nykode Therapeutics

Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies with a focus on the treatment of cancer and autoimmune diseases. Nykode's modular immunotherapy technology specifically targets antigens to antigen presenting cells (APC), which have been shown to induce a broad, strong and long-lasting antigen specific immune response in cancer, which correlates with clinical responses.

Nykode's lead product candidates are abi-suva, a therapeutic immunotherapy for the treatment of HPV16 induced malignancies which demonstrated favorable safety and efficacy results from its Phase 2 trial for the treatment of late-line r/m cervical cancer. Abi-suva is currently being further developed in first line head and neck cancer with the randomized Abili-T trial with interim results within 2027. VB10.NEO, an individualized cancer vaccine, has been investigated in two trials with more than 10 different indications.

Nykode is also utilizing its APC-targeted technology to create an immune tolerance platform for the potential use in autoimmune disorders, organ transplant rejections, anti-drug antibody reactions and allergy.

Nykode Therapeutics' shares are traded on the Oslo Stock Exchange (OSE: NYKD). Further information about Nykode Therapeutics can be found at http://www.nykode.com.

Forward-looking statements for Nykode Therapeutics

This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

Contact for Nykode Therapeutics ASA:

IR@nykode.com

Nykode Therapeutics ASA

Oslo Science Park
Gaustadalléen 21
N-0349 Oslo, Norway